ALB and neoplasm: The primary strategy for the delivery of albumin-encapsulated liposomes is based on the concept that liposomes with a size of ~200 nm can passively accumulate into the tumor and the inflammatory site (Figure 5), a process that is referred to as the enhanced permeability retention (EPR) effect [86,87].